Related Experiment Video
Updated: Apr 27, 2026
09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.2K
Targeted therapies for cutaneous T-cell lymphomas
Jason B Kaplan1, Joan Guitart, Francis J Giles
1Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, 645 N. Michigan Ave, Chicago, IL 60611, USA.
Expert Review of Hematology
|July 16, 2014
Summary
Cutaneous T-cell lymphomas (CTCLs) are rare skin cancers. This review explores targeted therapies for advanced CTCL, aiming to improve outcomes for mycosis fungoides and Sézary syndrome.
Area of Science:
- Oncology
- Dermatology
- Hematology
Background:
- Cutaneous T-cell lymphomas (CTCLs) are uncommon non-Hodgkin lymphomas primarily affecting the skin.
- CTCLs are generally incurable without allogeneic stem cell transplantation.
- Current treatments include skin-directed and systemic therapies, but unmet needs exist for advanced/refractory cases.
Purpose of the Study:
- To review targeted therapy options for CTCL.
- To focus on the two most studied subtypes: mycosis fungoides and Sézary syndrome.
- To address the need for therapies with favorable therapeutic indices in advanced CTCL.
Main Methods:
- Literature review of targeted therapies for CTCL.
- Analysis of treatment strategies for mycosis fungoides and Sézary syndrome.
- Discussion of current systemic therapeutic options and their limitations.
Main Results:
- CTCLs present a therapeutic challenge, often requiring aggressive treatment.
- Targeted therapies offer potential for improved outcomes in advanced and refractory CTCL.
- Infection susceptibility is a significant concern in advanced CTCL patients.
Conclusions:
- There is a critical need for novel targeted therapies for advanced and refractory CTCL.
- Focusing on mycosis fungoides and Sézary syndrome, targeted approaches may improve symptom control, cosmesis, and survival.
- Future research should prioritize developing treatments with favorable therapeutic indices to reduce infection risk.
Keywords:
Sézary syndromecutaneous T-cell lymphomahistone deacetylase inhibitorimmune checkpoint inhibitorimmunoconjugatemycosis fungoidesproteasome inhibitortargeted therapyMore Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:57Targeted Cancer Therapies
1.4K
1.4K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Cytotoxic T Cells-mediated Immune Response
7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161